ReviewFrontiers in cardiovascular medicine2022
Advances in pathogenesis and treatment of essential hypertension.
Review in Frontiers in cardiovascular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Circulating growth differentiation factor-15 concentration and hypertension risk: a dose-response meta-analysis.Frontiers in cardiovascular medicine · 2025Pooled it
- Pharmacokinetic and bioequivalence of two formulations of Valsartan/Amlodipine Tablet(I) in healthy Chinese volunteers: A randomized, three-period, partially replicated crossover study.Scientific reports · 2025Trial
- Efficacy and safety of community-based moxibustion for primary hypertension: A randomized controlled trial with patient preference arms.Journal of clinical hypertension (Greenwich, Conn.) · 2023Trial
- Role of miR-155 and miR-103 in Oxidative Stress in Cardiovascular Disease: A Narrative Review.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026Review
- Estimation of skin sodium content viaMagma (New York, N.Y.) · 2026Article
- Renal denervation triage tool: a practical approach to the management of resistant hypertension.AsiaIntervention · 2026Review
- Non-receptor tyrosine kinase signaling pathways and therapeutic implications.Signal transduction and targeted therapy · 2026Review
- Assessment of the quality and reliability of public health communication about hypertension on short video platforms in China.Frontiers in public health · 2026Article
- Weekend warriors, physical activity pattern and all-cause mortality: a prospective study of 150,145 Mexican adults with and without hypertension.BMC public health · 2025Article
- Stress, Anxiety, and Self-Efficacy in Hypertension: Evidence from a Romanian Case-Control Study.Diseases (Basel, Switzerland) · 2025Article
- A comprehensive narrative review on precision medicine approach to hypertension: exploring the role of genetics, epigenetics, microbiome, and artificial intelligence.Journal of health, population, and nutrition · 2025Review
- Prevalence and associated factors of comorbidities among hypertensive patients in Northwest Ethiopia, 2024.BMC cardiovascular disorders · 2025Article
- Review
- Central nervous system mechanisms of salt-sensitive hypertension.Physiological reviews · 2025Review
- Elevated Serum Trimethylamine N-Oxide Predicts Impaired Vascular Reactivity in Patients with Hypertension.Diagnostics (Basel, Switzerland) · 2025Article
- Effects of Zofenopril on Arterial Stiffness in Hypertension Patients.Molecular biotechnology · 2025Article
- Article
- Markers of Vascular Dysfunction in Hypertension.Current medicinal chemistry · 2025Review
- Physical activity and factors associated with the costs of low back pain among adults after 18 months of follow-up: a cohort study.Sao Paulo medical journal = Revista paulista de medicina · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertension is a significant risk factor for cardiovascular and cerebrovascular diseases and the leading cause of premature death worldwide. However, the pathogenesis of the hypertension, especially essential hypertension, is complex and requires in-depth studies. Recently, new findings about essential hypertension have emerged, and these may provide important theoretical bases and therapeutic tools to break through the existing bottleneck of essential hypertension. In this review, we demonstrated important advances in the different pathogenesis areas of essential hypertension, and highlighted new treatments proposed in these areas, hoping to provide insight for the prevention and treatment of the essential hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.